GlassScriptPhysician profile
Ganiyat A Adeyemo
NPI 1588113351
$2,532.39
in general payments reported to CMS, 2019-2025
15 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $206 · 2023: $691 · 2024: $866 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $546.07 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $448.01 | 2021-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $384.57 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $269.28 | 2023-2025 | Ingrezza |
| Tris Pharma INC | $176.41 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Janssen Pharmaceuticals, INC | $173.97 | 2021-2022 | |
| Corium, LLC | $127.67 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $101.92 | 2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $69.73 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $64.08 | 2023-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $60.65 | 2023-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $38.30 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.72 | 2021 | |
| Ironshore Pharmaceuticals INC. | $21.76 | 2024 | |
| Collegium Pharmaceutical, INC. | $16.25 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ganiyat Adeyemo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.